Table 1.
Circulating miRNAs as clinical biomarkers for detection of difficult-to-diagnose cancers.
| miRNA profiling | Test sample | Cancer Type | Healthy Control vs. Cancer | Study Reference | ||
|---|---|---|---|---|---|---|
| Sensitivity | Specificity | AUC (95% CI) | ||||
| miR-20a, miR-21, miR-25, miR-99a, miR-185, miR-191 | Serum | Pancreatic (PDAC) | 89% | 100% | 0.992 | [85] |
| miR-30c-5p, miR-let7e-5p, miR340-5p, miR-223-3p, miR-26a-5p, miR-340-3p, miR-335-5p, miR-23b-3p, miR-142-3p, miR-200c-3p, miR-148a-3p, miR-216a-5p, miR-145-5p, miR-200b-3p, miR-143-3p, miR-34a-5p, miR-429, miR-141-3p, miR-1260b, miR-145-3p, miR-216b-3p, miR-200a-3p, miR-1260a, miR-217-5p | Plasma and Serum | Pancreatic (PDAC) | 87% | 88% | 0.920 | [86] |
| miR-93-5p, miR-339-3p, miR-425-5p, miR-425-3p | Plasma | Pancreatic (PDAC) | 80% | 94.7% | 0.885 | [87] |
| miR-15b, miR-27b | Serum | Lung (NSCLC) | 100% | 84% | 0.980 | [88] |
| miR-155, miR-20a, miR-25, miR-296, miR-126, miR-223, miR-199a, miR-24, miR-152, miR-145, miR-let7f | Plasma | Lung (NSCLC) | 81.8% | 82.9% | 0.879 | [89] |
| miR-31-5p, miR-210-3p, miR21-5p | Sputum and Plasma | Lung (NSCLC) | 85.5% | 91.7% | 0.913 | [90] |
| miR-1247-5p, miR-301b-3p, miR-105-5p | Plasma | Lung (NSCLC) | 72.5% | 82.2% | 0.815 | [42] |
| miR-141 | Plasma | Lung (NSCLC) | 96.3% | 99.3% | 0.972 | [45] |
| miR-16 and miR-122 | Serum | Liver (HCC) | 58% | 84% | 0.803 | [91] |
| miR-206, miR-141-3p, miR-433-3p, miR-1228-5p, miR-199a-5p, miR-122-5p, miR-192-5p, miR-26a-5p | Serum | Liver (HCC) | 86% | 73% | 0.887 | [92] |
| miR-4661-5p, miR-4746-5p | Serum | Liver (HCC) | 85% | 89% | 0.942 | [93] |
| miR-92-3p, miR-107, miR-3126-5p | Serum | Liver (HCC) | 97.5% | 87.8% | 0.962 | [94] |
| miR-30e, miR-140 | CSF | CNS (Brain Tumour) | 76% | 75% | 0.776 | [56] |
| miR-15b | CSF | CNS (Glioma) | 90% | 94.9% | 0.960 | [95] |
| miR-15b | Plasma | CNS (Glioma) | 100% | 100% | 1.000 | [96] |
| miR-210 | Serum | CNS (Glioma) | 91.3% | 91.27% | 0.927 | [97] |
miR microRNA, AUC area under the curve, PDAC pancreatic ductal adenocarcinoma, NSCLC non-small cell lung cancer, HCC hepatocellular carcinoma; CSF cerebrospinal fluid, CNS central nervous system.